Reducing QT liability and proarrhythmic risk in drug discovery and development

Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative

(2009) Jonathan P. Piccini et al.   AMERICAN HEART JOURNAL

Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development

(2009) Vaibhav Salvi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Report and Recommendations of the Workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity

(2009) Tina C. Stummann et al.   Cardiovascular Toxicology

A framework to assess the translation of safety pharmacology data to humans

(2009) Jean-Pierre Valentin et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Beyond the safety assessment of drug-mediated changes in the QT interval… what's next?

(2009) Michael K. Pugsley et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays

(2009) Elena S. Trepakova et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Drug induced shortening of the QT/QTc interval: An emerging safety issue warranting further modelling and evaluation in drug research and development?

(2008) Mark Holbrook et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS